Lucatumumab (HCD122) 是一种全人抗 CD40 拮抗剂单克隆抗体，可阻断 CD40/ CD40L 介导的信号通路。Lucatumumab 可有效介导抗体依赖性细胞介导的细胞毒性 (ADCC) 和肿瘤细胞清除，可用于顽固性淋巴瘤、慢性淋巴细胞白血病 (CLL) 和多发性骨髓瘤研究。
| Cas No. | 903512-50-5 |
| 别名 | HCD122 |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research[1][2]. Lucatumumab (0.001-10 μg/mL; 4 h; 37 ℃) inhibit B-cell chronic lymphocytic leukemia (B-CLL) growth by ADCC-mediated cell lysis, with the average maximal lysis of B-CLL cells of 49%[1].
Lucatumumab (0.1-10 μg/mL; 3 d) inhibits CD40L-induced signaling and viability of B-CLL cells[1].
Lucatumumab (10 μg/mL; 24 h) inhibits cytokine secretion by B-CLL cells[1].
Cell Viability Assay[1] | Cell Line: | B-cell chronic lymphocytic leukemia (B-CLL) | | Concentration: | 0.001 to 10 μg/mL | | Incubation Time: | 72 hours; 37 ℃ | | Result: | Inhibited B-CLL growth with an ED50of 14 pM and a average maximal lysis of B-CLL cells of 49%. |
|
